# Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

> **NCT03682289** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Rahul Aggarwal** · enrollment: 83 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma
- Locally Advanced Pancreatic Cancer
- Locally Advanced Malignant Solid Neoplasm
- Metastatic Malignant Solid Neoplasm
- Metastatic Renal Cell Carcinoma
- Metastatic Urothelial Carcinoma
- Metastatic Pancreatic Cancer
- Stage III Pancreatic Cancer
- Stage III Renal Cell Cancer
- Stage IV Pancreatic Cancer
- Stage IV Renal Cell Cancer
- Endometrial Cancer
- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Ceralasertib
- **DRUG:** Olaparib
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT03682289
- **Lead sponsor:** Rahul Aggarwal
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-01-17
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03682289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03682289, "Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03682289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*